[HTML] sciencedirect.com

[HTML][HTML] First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial

LG Paz-Ares, SS Ramalingam, TE Ciuleanu… - Journal of Thoracic …, 2022 - Elsevier
Abstract Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …
被引用次数：268 相关文章

[引用][C] First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

LG Paz-Ares, SS Ramalingam, TE Ciuleanu… - Journal of Thoracic …, 2022 - cir.nii.ac.jp
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the
Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial | CiNii Research CiNii 国立 …

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

LG Paz-Ares, SS Ramalingam… - Journal of …, 2022 - mdanderson.elsevierpure.com
Abstract Introduction: In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

LG Paz Ares, M Provencio Pulla - Journal of Thoracic …, 2021 - repositorio.uam.es
In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus
chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or …

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

LG Paz-Ares, SS Ramalingam, TE Ciuleanu… - Journal of Thoracic …, 2021 - europepmc.org
Methods Adults with previously untreated stage IV or recurrent NSCLC were randomized (1:
1: 1) to nivolumab plus ipilimumab, nivolumab, or chemotherapy (PD-L1≥ 1%); or to …

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

LG Paz-Ares, SS Ramalingam… - Journal of thoracic …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS)
versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater …
[HTML] qut.edu.au

[HTML][HTML] First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

LG Paz-Ares, SS Ramalingam… - Journal of Thoracic …, 2022 - eprints.qut.edu.au
Introduction: In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS)
versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater …
[HTML] jto.org

[HTML][HTML] First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

LG Paz-Ares, SS Ramalingam, TE Ciuleanu… - Journal of Thoracic …, 2022 - jto.org
Abstract Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

LG Paz-Ares, SS Ramalingam… - Journal of …, 2022 - ohiostate.elsevierpure.com
Abstract Introduction: In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

L Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee… - 2022 - digital.csic.es
[Results] After 54.8 months' median follow-up, OS remained longer with nivolumab plus
ipilimumab versus chemotherapy in patients with PD-L1 greater than or equal to 1%(hazard …